Dr. Randall is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
UCSD Moores Cancer Center
3855 Health Science Drive, #0987
La Jolla, CA 92093Phone+1 858-822-6185Fax+1 858-249-0905
Summary
- Michael Randall, MD is an Oncology specialist with a subspecialty in Genitourinary Oncology based in La Jolla, CA. He graduated from the University of Alabama School of Medicine in 2005 and did his fellowship in Hematology and Medical Oncology, and residency in Internal Medicine at the University of California San Diego Medical Center. Currently a Clinical Professor at the University of California, San Diego, Dr. Randall has expertise in prostate cancer, kidney cancer, and bladder cancer. He has published research papers on various oncology topics and has considerable experience in conducting clinical trials. He received the CMS Meaningful Use Stage 1 Certification in 2012-2013.
Education & Training
- University of California (San Diego) Medical CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
- University of California (San Diego) Medical CenterResidency, Internal Medicine, 2005 - 2008
- University of Alabama School of MedicineClass of 2005
Certifications & Licensure
- CA State Medical License 2007 - 2026
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
Publications & Presentations
PubMed
- 8 citationsChange in platelet count as a prognostic indicator for response to primary tyrosine kinase inhibitor therapy in metastatic renal cell carcinomaZachary Hamilton, Hak J. Lee, Juan Jimenez, Brian R. Lane, Song Wang
BJU International. 2016-12-01 - 155 citationsHypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy.Yulian Khagi, Aaron M. Goodman, Gregory A. Daniels, Sandip Pravin Patel, Assuntina G. Sacco
Clinical Cancer Research. 2017-10-01 - 6 citationsGermline alterations among Hispanic men with prostate cancer.Elizabeth Pan, Justin Shaya, Lisa Madlensky, J Michael Randall, Juan Javier-Desloges
Prostate Cancer and Prostatic Diseases. 2022-09-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: